Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) (MANIFEST-2)

April 17, 2024 updated by: Constellation Pharmaceuticals

A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients

A Phase 3, randomized, blinded study comparing pelabresib (CPI-0610) and ruxolitinib with placebo and ruxolitinib in myelofibrosis (MF) patients that have not been previously treated with Janus kinase inhibitors (JAKi). Pelabresib is a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

430

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Australia
      • Buderim, Australia, QLD 4556
        • USC Clinical Trials Centre Sunshine Coast Haematology and Oncology Clinic
      • Nedlands, Australia, 6009
        • One Clinical Research Pty Ltd
      • North Adelaide, Australia
        • Calvary North Adelaide Hospital
    • New South Wales
      • Wahroonga, New South Wales, Australia, 2076
        • Sydney Adventist Hospital
    • Queensland
      • Brisbane, Queensland, Australia, 4101
        • Icon Cancer Centre
    • South Australia
      • Adelaide, South Australia, Australia, 5000
        • Royal Adelaide Hospital
    • Victoria
      • Clayton, Victoria, Australia, 3168
        • Monash Health
      • Frankston, Victoria, Australia, 3199
        • Peninsula Private Hospital Clinical Trials Unit
  • Austria
      • Graz, Austria, A-8036
        • LKH - Universitätsklinikum Graz; Abteilung für Hämatologie
      • Linz, Austria, 4020
        • Krankenhaus der Elisabethinen Linz
  • Belgium
      • Antwerpen, Belgium
        • ZNA
      • Brugge, Belgium
        • AZ Sint-Jan
      • Brussel, Belgium, 1200
        • Cliniques universitaires Saint-Luc
      • Jette, Belgium, 1090
        • UZ Brussel
      • La Louvière, Belgium, 7100
        • Hôpital de Jolimont
      • Leuven, Belgium
        • UZ Leuven
      • Liège, Belgium, 4000
        • Domaine Universitaire du Sart Tilman
  • Canada
      • Montréal, Canada, H1T 2M4
        • Hôpital Maisonneuve-Rosemont
      • Ottawa, Canada, K1H 8L6
        • The Ottawa Hospital General Campus
    • Alberta
      • Calgary, Alberta, Canada, T2N 4N2
        • Tom Baker Cancer Centre
      • Edmonton, Alberta, Canada, T6G 2B7
        • University of Alberta Hospital
    • Ontario
      • London, Ontario, Canada, N6A 5W9
        • London Health Sciences Center - Victoria Hospital
      • Toronto, Ontario, Canada, M5G 2M9
        • Princess Margaret Cancer Center
    • Quebec
      • Montréal, Quebec, Canada, H3T 1E2
        • Jewish General Hospital
  • Czechia
      • Hradec Kralove, Czechia, 500 05
        • Fakultni Nemocnice Hradec Kralove
      • Olomouc, Czechia, 779 00
        • University Hospital Olomouc
  • France
      • Amiens, France, 80054
        • CHU Amiens Picardie
      • Créteil, France, 94010 Cedex
        • CHU Henri-Mondor
      • Le Mans, France, 72000
        • Centre Hospitalier
      • Marseille, France, 13385
        • Hopital de la Conception
      • Nice, France, 06202
        • Hôpital l'Archet 1
      • Nîmes, France
        • CHU DE NIMES _Institut de Cancérologie du Gard
      • Paris, France
        • Centre d'Investigations Cliniques
      • Pierre-Bénite, France, 69310
        • Centre Hospitalier Lyon Sud Secteur 1G
      • Rennes, France, 35033
        • Chu Pontchaillou - Service Hematologie
      • Saint-Priest-en-Jarez, France, 42271
        • Institut de Cancérologie Lucien Neuwirth
      • Tours, France, 37044
        • Hôpital Bretonneau
      • Vandœuvre-lès-Nancy, France, 54500
        • CHRU Brabois
  • Germany
      • Hamburg, Germany, 20251
        • Universitätsklinikum Hamburg-Eppendorf (UKE), II. Medizinische Klinik und Poliklinik
    • Baden-Württemberg
      • Ulm, Baden-Württemberg, Germany, 89081
        • Universitätsklinikum Ulm
    • Bayern
      • Augsburg, Bayern, Germany, 86151
        • Hämatologisch-Onkologische Praxis Augsburg
    • Nordrhein-Westfalen
      • Minden, Nordrhein-Westfalen, Germany, 32429
        • Johannes Wesling Klinikum Minden
    • Sachsen
      • Chemnitz, Sachsen, Germany, 09116
        • Klinikum Chemnitz, Innere Medizin III
      • Halle, Sachsen, Germany, 06120
        • Universitätsklinikum Halle (Saale), Krukenberg-Krebszentrum Halle (KKH)
    • Thüringen
      • Jena, Thüringen, Germany, 07747
        • Universitätsklinikum Jena, Klinik für Innere Medizin II
  • Greece
      • Alexandroupolis, Greece
        • University Hospital of Alexandroupolis
      • Athens, Greece
        • Laiko General Hospital
      • Athens, Greece
        • General Hospital, School of Medicine National and Kapodistrian University of Athens
      • Athens, Greece
        • Ηippokration General Hospital
  • Hong Kong
    • Kowloon
      • Hong Kong, Kowloon, Hong Kong
        • Princess Margaret Hospital
    • New Territories
      • Hong Kong, New Territories, Hong Kong
        • Prince of Wales Hospital
  • Hungary
      • Budapest, Hungary, 1088
        • Semmelweis University - Internal Medicine and Oncology Clinic
      • Debrecen, Hungary, 4032
        • Debreceni Egyetem Klinikai Kozpont, Belgyogyaszati Klinika, Hematologia
      • Gyor, Hungary, 9024
        • Petz Aladar Egyetemi Oktato Korhaz
      • Nyíregyháza, Hungary
        • Szabolcs Szatmár Bereg Megyei Kórházak és Egyetemi Oktatókórház; Jósa András Oktatókórház, Hematológia
    • Pecs
      • Pécs, Pecs, Hungary, 7624
        • : Pecs University, 1st Department of Medicine
  • Israel
      • Ashkelon, Israel, 7830604
        • Barzilai Medical Center
      • Be'er Sheva, Israel, 84101
        • Soroka Medical Center
      • Be'er Ya'aqov, Israel, 60930000
        • Shamir medical center
      • Haifa, Israel, 3109601
        • Rambam Health Corporation
      • Haifa, Israel, 3436212
        • Lady Davis Carmel Medical Center
      • H̱olon, Israel
        • Wolfson Medical Center
      • H̱olon, Israel, Itayz@wmc.gov.il
        • Wolfson Medical Center
      • Jerusalem, Israel, 9103102,
        • Shaarei Zedek
      • Jerusalem, Israel, 9590300
        • Hadassah University Hospital-Ein Kerem
      • Nahariya, Israel, 2210001
        • Shaarei Zedek
      • Petah Tikva, Israel, 49100
        • Rabin Medical Center - Beilinson Campus,
      • Ramat Gan, Israel, 5265601
        • Sheba Medical Center
      • Reẖovot, Israel, 76100
        • Kaplan Medical Center
      • Tel Aviv, Israel, 6423906
        • Tel Aviv Sourasky Medical Center
  • Italy
      • Bergamo, Italy, 24127
        • Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII
      • Bologna, Italy, 40138
        • A.O.U. Policlinico S. Orsola-Malpighi
      • Catania, Italy
        • AOU Policlinico G. Rodolico - San Marco
      • Ferrara, Italy
        • Azienda Ospedaliera Universitaria Arcispedale Sant'Anna
      • Florence, Italy
        • Azienda Ospedaliera Universitaria Careggi
      • Genova, Italy
        • Ospedale Policlinico San Martino IRCCS
      • Meldola, Italy
        • IRCCS Istituto Romagnolo per lo studio dei tumori "Dino Amadori"
      • Milano, Italy
        • Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico
      • Monza, Italy
        • Azienda Ospedaliera San Gerardo di Monza
      • Orbassano, Italy
        • AOU S.Luigi Gonzaga
      • Rome, Italy
        • Ospedale Sant'Eugenio
      • Varese, Italy
        • Ospedale di Circolo e Fondazione Macchi - ASST Sette Laghi
  • Korea, Republic of
      • Busan, Korea, Republic of
        • Inje University Busan Paik Hospital
      • Busan, Korea, Republic of, 49241
        • Pusan National University Hospital
      • Busan, Korea, Republic of, 48108
        • Inje University Haeundae Paik Hospital
      • Daegu, Korea, Republic of
        • Daegu Catholic University Medical Center
      • Daegu, Korea, Republic of
        • Keimyung University Dongsan Hospital
      • Daegu, Korea, Republic of, 41944
        • Kyungpook National University Hospital
      • Gyeonggi-do, Korea, Republic of
        • Cha Bundang Medical Center Cha University
      • Gyeonggi-do, Korea, Republic of
        • The Catholic University Of Korea St. Vincent Hospital
      • Incheon, Korea, Republic of
        • Gachon University Gil Medical Center
      • Jeonju, Korea, Republic of, 54907
        • Jeonbuk National University Hospital
      • Seoul, Korea, Republic of
        • Seoul National University Hospital
      • Seoul, Korea, Republic of, 135-710
        • Samsung Medical Center
      • Seoul, Korea, Republic of, 03722
        • Severance Hospital, Yonsei University Health System
      • Seoul, Korea, Republic of
        • Korea University Anam Hospital
      • Seoul, Korea, Republic of
        • Hanyang University Medical Center
      • Seoul, Korea, Republic of
        • The Catholic University of Korea
      • Seoul, Korea, Republic of, 08307
        • Korea University Guro Hospital
      • Seoul, Korea, Republic of
        • The Catholic University of South Korea Seoul St. Mary's Hospital
      • Ulsan, Korea, Republic of
        • Ulsan University Hospital
    • Gyeonggi-do
      • Goyang-si, Gyeonggi-do, Korea, Republic of, 10408
        • National Cancer Center
    • Gyeongsangnam-do
      • Jinju-si, Gyeongsangnam-do, Korea, Republic of
        • Gyeongsang National University Hospital
  • Malaysia
      • Kuala Lumpur, Malaysia, 59100
        • University Malaya Medical Centre
    • Johor
      • Johor Bahru, Johor, Malaysia, 80100
        • Hospital Sultanah Aminah
    • Kedah
      • Alor Setar, Kedah, Malaysia, 05460
        • Hospital Sultanah Bahiyah
    • Penang
      • George Town, Penang, Malaysia, 10450
        • Hospital Pulau Pinang
    • Selangor
      • Ampang, Selangor, Malaysia, 68000
        • :Hospital Ampang
      • Petaling Jaya, Selangor, Malaysia, 47500
        • Sunway Medical Centre
  • Netherlands
      • Amsterdam, Netherlands, 1081
        • Amsterdam UMC
      • Maastricht, Netherlands, 6229 HX
        • Maastricht University Medical Center
  • Poland
      • Biała Podlaska, Poland, 21-50
        • Wojewódzki Szpital Specjalistyczny w Bialej Podlaskiej
      • Gdańsk, Poland, 80-293
        • Uniwersyteckie Centrum Kliniczne
      • Katowice, Poland
        • Pratia Onkologia Katowice
      • Skorzewo, Poland, 60-185
        • Centrum Medyczne Pratia
      • Toruń, Poland, 87-100
        • Nasz Lekarz Przychodnie Medyczne
  • Spain
      • Badalona, Spain, 8916
        • ICO Badalona - Hospital Universitari Germans Trias i Pujol
      • Barcelona, Spain
        • Hospital Clinic De Barcelona
      • Barcelona, Spain
        • Vall d'Hebron Institute of Oncology
      • Burgos, Spain, 09006
        • Hospital Universitario De Burgos
      • Caceres, Spain, 10003
        • Hospital San Pedro de Alcantara
      • Girona, Spain
        • ICO Girona - Hospital Universitari de Girona
      • Las Palmas de Gran Canaria, Spain, 35010
        • Hospital Universitario de Gran Canaria Dr. Negrin
      • Madrid, Spain, 28040
        • Hospital Universitario Fundación Jiménez Díaz
      • Pamplona, Spain, 31008
        • Complejo Hospitalario de Navarra
      • Salamanca, Spain, 37007
        • Hospital Universitario de Salamanc
      • Sevilla, Spain
        • Hospital Virgen Macarena
      • Valencia, Spain, 46010
        • Hospital Clinico Universitario de Valencia
    • Asturias
      • Oviedo, Asturias, Spain, 33011
        • Hospital Universitario Central de Asturias
  • Taiwan
      • Chiayi City, Taiwan
        • Chang Gung Memorial Hospital Chiayi
      • Chiayi City, Taiwan
        • China Medical University Hospital
      • Kaohsiung, Taiwan
        • Kaohsiung Medical University Chung-Ho Memorial Hospital
      • Taichung, Taiwan
        • Taichung Veterans General Hospital
      • Taipei, Taiwan
        • National Taiwan University Hospital
  • Thailand
    • Hat Yai District
      • Songkla, Hat Yai District, Thailand, 90110
        • Songklanagarind Hospital
    • Lak Si
      • Bangkok, Lak Si, Thailand, 10210
        • Chulabhorn Hospital
    • Mueang Khon Kaen District
      • Khon Kaen, Mueang Khon Kaen District, Thailand, 40002
        • Srinagarind hospital,Khon Kaen University
    • Pathumwan
      • Bangkok, Pathumwan, Thailand, 10330
        • King Chulalongkorn Memorial Hospital
    • Ratchathewi District
      • Bangkok, Ratchathewi District, Thailand, 10400
        • Rajavithi Hospital
  • Turkey
      • Ankara, Turkey
        • Ankara University Faculty of Medicine Cebeci Research and Application Hospital
      • Ankara, Turkey
        • Dr. Abdurrahman Yurtaslan Oncology Health Application and Research Center
      • Antalya, Turkey
        • Antalya Medstar Hospital
      • Edirne, Turkey
        • Edirne Trakya University Faculty of Medicine Hospital
      • Gaziantep, Turkey
        • Gaziantep University Sahinbey Research and Application Center Hospital
      • Kocaeli, Turkey
        • Kocaeli University Application
      • Mersin, Turkey
        • Mersin University
      • Samsun, Turkey
        • Samsun 19 Mayıs University Health Application Research Hospital
      • İzmir, Turkey
        • Izmir Ege University Faculty of Medicine Hospital
  • United Kingdom
      • Boston, United Kingdom, PE21 9QS
        • Pilgrim Hospital
      • Cambridge, United Kingdom, CB2 0QQ
        • Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust
      • London, United Kingdom, W12 0HS
        • Imperial College Healthcare NHS Trust, Hammersmith Hospital
      • London, United Kingdom
        • University College London Hospitals
      • Oxford, United Kingdom
        • Oxford University Hospitals NHS Foundation Trust, Department of Haematology, Cancer and Haematology Centre, Churchill Hospital
    • Scotland
      • Edinburgh, Scotland, United Kingdom, EH4 2XU
        • Western General Hospital
    • Wales
      • Cardiff, Wales, United Kingdom, CF14 4XW
        • University Hospital of Wales
  • United States
    • Alabama
      • Birmingham, Alabama, United States, 35294-3300
        • University of Alabama at Birmingham
    • Arizona
      • Chandler, Arizona, United States, 85224
        • Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers
    • California
      • La Jolla, California, United States, 92093
        • UC San Diego Moores Cancer Center
      • Los Angeles, California, United States, 90095
        • UCLA Medical Center
      • Los Angeles, California, United States, 90033
        • USC/Norris Comprehensive Cancer Center
    • Connecticut
      • New Haven, Connecticut, United States, 06510
        • Yale University School of Medicine
    • District of Columbia
      • Washington, District of Columbia, United States, 20007
        • Georgetown University
    • Florida
      • Jacksonville, Florida, United States, 32224
        • Mayo Clinic
      • Miami, Florida, United States, 33136
        • University of Miami Hospital
      • Tampa, Florida, United States, 33612
        • Moffitt Cancer Center
    • Illinois
      • Chicago, Illinois, United States, 60637
        • University of Chicago Medical Center
      • Chicago, Illinois, United States, 60611-5975
        • Northwestern
      • Decatur, Illinois, United States, 62526
        • Decatur Memorial Hospital Cancer Care Center of Decatur/Cancer Care Specialists of IL
      • Maywood, Illinois, United States, 60153
        • Loyola University - Cardinal Bernardin Cancer Center
    • Indiana
      • Indianapolis, Indiana, United States, 46237
        • Franciscan Health/Indiana blood and Marrow Transplantation
    • Kentucky
      • Louisville, Kentucky, United States, 40207
        • Norton Cancer Institute, St. Matthews Campus
    • Michigan
      • Ann Arbor, Michigan, United States, 48109
        • University of Michigan Medical Center
    • Missouri
      • Saint Louis, Missouri, United States, 63110
        • Washington University
    • Nevada
      • Reno, Nevada, United States, 89511
        • Cancer Care Specialists
    • New Jersey
      • Florham Park, New Jersey, United States, 07932
        • Summit Medical Group - Cancer Center
    • New York
      • New York, New York, United States, 10065
        • Memorial Sloan Kettering Cancer Center
      • New York, New York, United States, 10029
        • Icahn School of Medicine at Mount Sinai
      • New York, New York, United States, 10065
        • Weill Cornell Medical College- New York Presbyterian Hospital
    • Ohio
      • Cleveland, Ohio, United States, 44195
        • Cleveland Clinic Taussig Cancer Center
    • Oregon
      • Portland, Oregon, United States, 97239
        • Oregon Health and Science University
    • Texas
      • Houston, Texas, United States, 77030
        • MD Anderson Cancer Center
      • San Antonio, Texas, United States, 78229
        • Mays Cancer Center at UT Health San Antonio MD Anderson
    • Washington
      • Seattle, Washington, United States, 98104
        • Center for Blood Disorders and Cellular Therapy, Swedish Cancer Institute

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Aged ≥ 18 years
  • Confirmed diagnosis of myelofibrosis (primary, post-polycythemia vera, or post essential thrombocythemia)
  • Adequate hematologic, renal, and hepatic function
  • Have at least 2 symptoms with an average score ≥ 3 or an average total score of ≥ 10 over the 7-day period prior to randomization using the MFSAF v4.0
  • Prognostic risk-factor score of Intermediate-1 or higher per Dynamic International Prognostic Scoring System (DIPSS) scoring system
  • Spleen volume of ≥ 450 cm^3
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

Exclusion Criteria:

  • Splenectomy or splenic irradiation in the previous 6 months
  • Chronic or active conditions and/or concomitant medication use that would prohibit treatment
  • Had prior treatment with any JAKi or BET inhibitor for treatment of a myeloproliferative neoplasm

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Pelabresib + ruxolitinib
Pelabresib monohydrate tablets + ruxolitinib phosphate tablets
Drug: Pelabresib

Double-blind treatment (pelabresib or matching placebo) will be administered daily for 14 consecutive days followed by a 7-day break, which is considered 1 cycle of treatment (1 cycle = 21 days).

Pelabresib is a small molecule inhibitor of BET proteins with a novel mechanism of action and potential for disease-modifying effects in MF.

Drug: Ruxolitinib
Ruxolitinib is a JAK inhibitor and a current, approved treatment option for MF.
Active Comparator: Placebo + ruxolitinib
Matching placebo tablets + ruxolitinib phosphate tablets
Drug: Ruxolitinib
Ruxolitinib is a JAK inhibitor and a current, approved treatment option for MF.
Drug: Placebo
Placebo tablets are designed to match pelabresib tablets. Each placebo tablet contains no active pharmaceutical ingredient and is visibly identical to experimental drug in size, shape, and packaging. Placebo dosing follows the same dosing conventions as pelabresib.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Splenic response at Week 24
Time Frame: 24 weeks of treatment
The primary endpoint of the study is splenic response, defined as a ≥35% reduction from baseline in spleen volume as measured by magnetic resonance imaging (MRI) or computerized tomography (CT), at Week 24.
24 weeks of treatment

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Total Symptom Score absolute change from baseline to Week 24
Time Frame: 24 weeks of treatment
A key secondary endpoint of the study is the absolute change in Total Symptom Score at Week 24 compared to baseline as measured by the Myelofibrosis Symptom Assessment Form v4.0. A higher Total Symptom Score indicates a higher disease burden and thus a worse outcome.
24 weeks of treatment
Total Symptom Score response at Week 24
Time Frame: 24 weeks of treatment
A key secondary endpoint of the study is Total Symptom Score response, defined as a ≥50% decrease from baseline in Total Symptom Score as measured by the Myelofibrosis Symptom Assessment Form v4.0, at Week 24. A higher Total Symptom Score indicates a higher disease burden and thus a worse outcome.
24 weeks of treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Constellation Pharmaceuticals

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 9, 2021

Primary Completion (Actual)

August 24, 2023

Study Completion (Estimated)

December 1, 2027

Study Registration Dates

First Submitted

October 20, 2020

First Submitted That Met QC Criteria

October 21, 2020

First Posted (Actual)

October 26, 2020

Study Record Updates

Last Update Posted (Estimated)

April 18, 2024

Last Update Submitted That Met QC Criteria

April 17, 2024

Last Verified

March 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CPI 0610-04
  • 2020-001989-10 (EudraCT Number)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Primary Myelofibrosis

Clinical Trials on Pelabresib

  • Constellation Pharmaceuticals
    Completed
    Study Evaluating Food Effect and QTc in Patients With Advanced Malignancies
    Solid Tumor | Advanced Malignancies | Hematological Malignancy
    Spain, United States, Georgia
  • Constellation Pharmaceuticals
    The Leukemia and Lymphoma Society
    Active, not recruiting
    A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis
    Neoplasms | Neoplasms by Histologic Type | Leukemia | Preleukemia | Primary Myelofibrosis | Myeloproliferative Disorders | Myelofibrosis | Precancerous Conditions | Myelodysplastic/Myeloproliferative Neoplasm | Myelodysplastic Syndrome (MDS) | Leukemia, Myelocytic, Acute | Bone Marrow Disease | Hematological Disease and other conditions
    Canada, United States, United Kingdom, Germany, Italy, Belgium, France, Netherlands, Poland

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Colombia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe